SEC Form SC 13D/A filed by Syneos Health, Inc. (Amendment)
$SYNH
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2023 | $30.00 → $28.00 | Neutral → Underweight | JP Morgan |
| 1/17/2023 | $30.00 → $25.00 | Overweight → Underweight | Barclays |
| 1/13/2023 | $25.00 | Overweight → Underweight | Barclays |
| 12/14/2022 | $66.00 → $38.00 | Buy → Neutral | Mizuho |
| 11/7/2022 | $55.00 → $27.00 | Outperform → In-line | Evercore ISI |
| 10/18/2022 | $85.00 → $53.00 | Overweight → Neutral | JP Morgan |
| 9/14/2022 | Buy → Neutral | Guggenheim | |
| 9/7/2022 | $68.00 | Neutral | UBS |
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
4 - Syneos Health, Inc. (0001610950) (Issuer)
JP Morgan downgraded Syneos Health from Neutral to Underweight and set a new price target of $28.00 from $30.00 previously
Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00 from $30.00 previously
Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00
15-12G - Syneos Health, Inc. (0001610950) (Filer)
8-K - Syneos Health, Inc. (0001610950) (Filer)
S-8 POS - Syneos Health, Inc. (0001610950) (Filer)
JERSEY CITY, N.J., April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in the United States (U.S.). In 2016, MTPA was created as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of developing and advancing the company's pipeline in the U.S. while focusing on improving research in the areas of amyotrophic lateral sclerosis (ALS), erythropoietic protoporphyria (EPP), Parkinson's disease, spinal cord injury and systemic sclerosis. "For almost a decade, MT
Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight results from Phase 3 BouNDless trial in PD and real-world findings from preliminary analysis of RADICAVA® (edaravone) treatment in ALSJERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024. The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).
Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J., April 8, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS). The FDA's Orphan Drug program is designed to support the development of drugs that treat rare diseases which affect less than 200,000 people in the U.S. Previously, the FDA granted RADIC
MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company's stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing o
Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management ("Elliott"), Patient Square Capital ("Patient Square"), and Veritas Capital ("Veritas") for $43.00 per share in cash in a transaction valued at approximately $7.1 billion, including outstanding debt. The purchase price represents a
MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 10th, 2023, prior to its earnings call at 8:00 a.m. ET. To listen only and view the presentation slides via the live webcast, join from the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate in the conference, please register in advance at this link. Upon registration, all participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uni
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and
NEW YORK, Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE:CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE:HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29. Elliot Investment Management is acquiring Syneos Health in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector September 29, 2023 S&P MidCap 400 Addition Civitas Resources
MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organization to drive exceptional delivery, quality and data integrity for customers, while ensuring a positive experience for sponsors, sites and patients. Her investigator background, and technology and data experience, will empower the Clinical Sites & Patients team to execute data-driven solutions that produce strong results for customers. Under Dr. Haring'